Premalignant hematology patients categorized as monoclonal B-cell lymphocytosis, clonal cytopenia of indeterminate importance, monoclonal gammopathy of unknown relevance, and clonal hematopoiesis. These disorders are categorized as premalignant due to their clonal proliferation of myeloid, lymphoid, or plasma cells, without meeting the criteria for active hematologic malignancy or precancers; clinical manifestations, diagnosis, and management of these conditions are critical components of this topic. This review encompasses the most recently published articles and studies relevant to the article titles and the methodologies of isolation conducted without electronic instruments. The purpose of this review paper is to draw attention to the challenges related to bleeding, thrombosis, and diagnosis. The articles' outcomes rely on changes in treatment and diagnosis, as there has been no acceptable medication for a long time. One of the most common problems is side effects during therapy, like infections and neutropenia, which have resulted in one treatment-related death. Considering the connection between thrombosis and therapy in premalignant patients, when there is insufficient information to accept the excess bleeding and thrombosis in premalignant hematological patients.